Phosphatidylserine receptor-targeting therapies for the treatment of cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phosphatidylserine receptor-targeting therapies for the treatment of cancer
Authors
Keywords
Phosphatidylserine, Phosphatidylserine receptor, TAM receptor, Cancer
Journal
ARCHIVES OF PHARMACAL RESEARCH
Volume 42, Issue 7, Pages 617-628
Publisher
Springer Science and Business Media LLC
Online
2019-06-07
DOI
10.1007/s12272-019-01167-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immuno-Oncological Efficacy of RXDX-106, a Novel Small Molecule Inhibitor of the TAM (TYRO3, AXL, MER) Family of Kinases
- (2019) Yumi Yokoyama et al. CANCER RESEARCH
- Tumor-secreted Pros1 inhibits macrophage M1 polarization to reduce antitumor immune response
- (2018) Eric Ubil et al. JOURNAL OF CLINICAL INVESTIGATION
- Axl inhibitors as novel cancer therapeutic agents
- (2018) Yingying Shen et al. LIFE SCIENCES
- Targeting Gas6/TAM in cancer cells and tumor microenvironment
- (2018) Guiling Wu et al. Molecular Cancer
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib
- (2018) Luís Eduardo Zucca et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Design and Synthesis of Novel 2,4-Diamino-5-pyrazol-4-yl Pyrimidine Derivatives as Selective Tyro3 Kinase Inhibitors
- (2018) Dukwoon Kim et al. BULLETIN OF THE KOREAN CHEMICAL SOCIETY
- Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma
- (2018) Lenka Sinik et al. MOLECULAR CANCER THERAPEUTICS
- The Emerging Role of TYRO3 as a Therapeutic Target in Cancer
- (2018) Sherri Smart et al. Cancers
- Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
- (2017) Peter P. Ruvolo et al. HAEMATOLOGICA
- A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma
- (2017) Tasnuva D. Kabir et al. HEPATOLOGY
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice
- (2017) Tal Gefen et al. MOLECULAR THERAPY
- Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
- (2017) Peter P. Ruvolo et al. HAEMATOLOGICA
- Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
- (2016) Le Qu et al. CANCER CELL
- Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease and cancer
- (2016) R B Birge et al. CELL DEATH AND DIFFERENTIATION
- Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis
- (2016) Wilhem Leconet et al. CLINICAL CANCER RESEARCH
- UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models
- (2016) Deborah DeRyckere et al. CLINICAL CANCER RESEARCH
- Sunitinib activates Axl signaling in renal cell cancer
- (2016) Johannes C. van der Mijn et al. INTERNATIONAL JOURNAL OF CANCER
- Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer
- (2016) Peter B. Alexander et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The TAM family receptor tyrosine kinase TYRO3 is a negative regulator of type 2 immunity
- (2016) P. Y. Chan et al. SCIENCE
- Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors
- (2016) Xiaodong Wang et al. ACS Medicinal Chemistry Letters
- AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity
- (2016) Edward T Schmid et al. eLife
- Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
- (2015) S. Sinha et al. CLINICAL CANCER RESEARCH
- AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
- (2015) Samuel H. Myers et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- An Apoptotic ‘Eat Me’ Signal: Phosphatidylserine Exposure
- (2015) Katsumori Segawa et al. TRENDS IN CELL BIOLOGY
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
- (2015) Parag P. Patwardhan et al. Oncotarget
- TIMgenes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity
- (2015) Gordon J. Freeman et al. IMMUNOLOGICAL REVIEWS
- Regulation of T cell responses by the receptor molecule Tim-3
- (2014) Jacob V. Gorman et al. IMMUNOLOGIC RESEARCH
- Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution
- (2014) Jamie C. Stanford et al. JOURNAL OF CLINICAL INVESTIGATION
- Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
- (2014) Robert L. Ferris et al. JOURNAL OF IMMUNOLOGY
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
- (2014) Magdalena Paolino et al. NATURE
- Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia
- (2013) R. M. A. Linger et al. BLOOD
- MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation
- (2013) J. K. Rho et al. CANCER RESEARCH
- NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants
- (2013) Jae-Sik Shin et al. INVESTIGATIONAL NEW DRUGS
- MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis
- (2013) Rebecca S. Cook et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia
- (2013) L N Brandao et al. Blood Cancer Journal
- Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation
- (2013) Y. Yin et al. Cancer Immunology Research
- Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase
- (2012) Noel A. Powell et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase
- (2012) Noel A. Powell et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Efficient Clearance of Early Apoptotic Cells by Human Macrophages Requires M2c Polarization and MerTK Induction
- (2012) G. Zizzo et al. JOURNAL OF IMMUNOLOGY
- Targeting Axl With an High-affinity Inhibitory Aptamer
- (2012) Laura Cerchia et al. MOLECULAR THERAPY
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Novel and selective spiroindoline-based inhibitors of sky kinase
- (2011) Noel A. Powell et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer
- (2011) E. Avilla et al. CANCER RESEARCH
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments
- (2011) Douglas D. Taylor et al. Seminars in Immunopathology
- Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors
- (2011) Alexis Mollard et al. ACS Medicinal Chemistry Letters
- The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy
- (2010) A. K. Ghosh et al. BLOOD
- R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
- (2010) S. J. Holland et al. CANCER RESEARCH
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- TIM-4, a Receptor for Phosphatidylserine, Controls Adaptive Immunity by Regulating the Removal of Antigen-Specific T Cells
- (2010) L. A. Albacker et al. JOURNAL OF IMMUNOLOGY
- Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
- (2010) V. Dardalhon et al. JOURNAL OF IMMUNOLOGY
- T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells
- (2010) Rosemarie H. DeKruyff et al. JOURNAL OF IMMUNOLOGY
- TNF-α, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/macrophages
- (2010) Federica Alciato et al. JOURNAL OF LEUKOCYTE BIOLOGY
- BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro
- (2010) Y. Dai et al. MOLECULAR CANCER THERAPEUTICS
- AXL regulates mesothelioma proliferation and invasiveness
- (2010) W-B Ou et al. ONCOGENE
- An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
- (2010) X Ye et al. ONCOGENE
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
- (2010) H.-T. Jin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6
- (2009) S. Loges et al. BLOOD
- The ins and outs of phospholipid asymmetry in the plasma membrane: roles in health and disease
- (2009) Bengt Fadeel et al. CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Discovery ofN-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
- (2009) Gretchen M. Schroeder et al. JOURNAL OF MEDICINAL CHEMISTRY
- Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
- (2009) Y Li et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search